Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

BACKGROUND: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Respir Med
Main Authors: Heaney, Liam G, Busby, John, Hanratty, Catherine E, Djukanovic, Ratko, Woodcock, Ashley, Walker, Samantha M, Hardman, Timothy C, Arron, Joseph R, Choy, David F, Bradding, Peter, Brightling, Christopher E, Chaudhuri, Rekha, Cowan, Douglas C, Mansur, Adel H, Fowler, Stephen J, Niven, Robert M, Howarth, Peter H, Lordan, James L, Menzies-Gow, Andrew, Harrison, Tim W, Robinson, Douglas S, Holweg, Cecile T J, Matthews, John G, Pavord, Ian D
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783382/
https://ncbi.nlm.nih.gov/pubmed/32916135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(20)30397-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki